Concord Biotech to Invest in 12.6 MW Wind‑Solar Hybrid Project in Gujarat

What Concord Biotech announced

Concord Biotech Ltd filed a Regulation 30 (LODR) announcement on 20 June 2026 stating that it has entered into an agreement to invest in M/s. FSGE Renewable Power Private Limited. The purpose of the investment is to install a wind‑solar hybrid power project for Concord’s Limbasi facility in Gujarat.

"We are pleased to announce that the Company has entered into an agreement to Invest in M/s. FSGE Renewable Power Private Limited for installation of Wind Solar Hybrid Power Project having a wind capacity of approximately 6.3 MW AC & solar capacity of approximately 6.3 MWp DC in Gujarat for Limbasi Facility of the Company."

Investment and partnership details

The agreement is a strategic partnership with FSGE Renewable Power Private Ltd, a developer of renewable‑energy assets. While the filing confirms the intent to invest, it does not disclose the financial size of the commitment. The arrangement is classified as an acquisition‑type transaction under the Listing Obligations and Disclosure Requirements (LODR).

Project specifics

• Location: Gujarat, India – site identified as the Limbasi Facility of Concord Biotech.
• Wind capacity: Approximately 6.3 MW (AC).
• Solar capacity: Approximately 6.3 MWp (DC).
• Technology: Hybrid configuration combining wind turbines and photovoltaic panels to provide a more stable power supply.
• Developer: FSGE Renewable Power Private Ltd, which will handle design, procurement, construction, and commissioning.

Key facts at a glance

Why this matters for investors

The move signals Concord Biotech’s intent to diversify its energy sourcing and reduce reliance on grid electricity for its manufacturing operations. By securing a dedicated renewable‑energy source, the company may achieve lower long‑term power costs and improve sustainability credentials, which are increasingly scrutinised by stakeholders. However, because the monetary commitment is not disclosed, investors cannot immediately assess the dilution impact or balance‑sheet implications. The transaction also falls under LODR, meaning it will be subject to standard disclosure and shareholder‑approval processes as required.

Conclusion

Concord Biotech has committed to a 12.6 MW wind‑solar hybrid project in Gujarat through an agreement with FSGE Renewable Power. While the capacity and strategic intent are clear, the financial terms remain undisclosed, and further regulatory approvals may be required before the project proceeds to construction.